Skip to main content

Insights into new anticoagulants

 Prof Meyer Michel Samama, Prof Hugo ten Cate

In this Thrombosis Journal series, the greater simplicity and potential of a new class of direct-action oral anticoagulants (DOACs) is explored along with the new challenges they present.

This thematic series has not been sponsored. Articles have been invited by the journal, and have undergone the standard peer review process overseen by the Guest Editors.

MMS declares no conflict of interest. HTC, Chairman of the Dutch Foundation of Anticoagulation Services, has received fees for lectures and consultation from several industries involved in diagnostic anticoagulation tests, or the development of direct-action oral anticoagulants.

  1. Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

    Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier
    Citation: Thrombosis Journal 2014 12:24
  2. Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of whic...

    Authors: Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde and Jean-Luc Martinoli
    Citation: Thrombosis Journal 2013 11:11
  3. Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban d...

    Authors: Wolfgang Mueck, Stephan Schwers and Jan Stampfuss
    Citation: Thrombosis Journal 2013 11:10